Lantheus Holdings, Inc.
Lantheus Holdings, Inc. (LNTH): 21 pipeline candidates · 3 upcoming catalysts · ~20 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
19.6 months
D/E 0.94 · 1% dilution
Lead: Approved
21 candidates
3 upcoming, next in ~1726d
N/A
A transparent, data-derived signal for Lantheus Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.7B
Cash
$500.3M
Quarterly Burn
$96.9M
Runway
19.6 mo
Revenue
$377.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (21 candidates)
| Drug | Phase |
|---|---|
| aBSI (Automated Bone Scan Index) | Approved |
| aPROMISE (commercialized as PYLARIFY AI in the U.S.) | Approved |
| CARDIOLITE | Approved |
| DEFINITY | Approved |
| LNTH-2401 | Preclinical |
| LNTH-2402 | Preclinical |
| lnth-2403 | Preclinical |
| LRRC15 monoclonal antibody | Preclinical |
| MK-6240 | N/A |
| NAV-4694 | Preclinical |
Showing 10 of 21 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
403
Total value held
$5.91B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 9,549,682 | $724.3M |
| blackrock, inc. | 8,183,193 | $620.7M |
| vanguard capital management llc | 5,828,628 | $442.1M |
| farallon capital management llc | 5,583,479 | $423.5M |
| fmr llc | 4,626,453 | $350.9M |
| vanguard portfolio management llc | 3,174,274 | $240.8M |
| state street corp | 2,429,803 | $184.3M |
| american century companies inc | 1,781,106 | $135.1M |
| geode capital management, llc | 1,765,952 | $134.0M |
| morgan stanley | 1,646,463 | $124.9M |
Showing top 10 of 403 institutional holders of Lantheus Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lantheus Holdings, Inc.'s pipeline?
Lantheus Holdings, Inc. (LNTH) has 21 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lantheus Holdings, Inc.'s lead drug candidate?
Lantheus Holdings, Inc.'s most advanced tracked candidate is aBSI (Automated Bone Scan Index) (Approved) for automatically calculates disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions.
What is Lantheus Holdings, Inc.'s next catalyst?
Lantheus Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: RELISTOR" — expected March 10, 2031.
What is Lantheus Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lantheus Holdings, Inc. has approximately 19.6 months of cash runway.
What is Lantheus Holdings, Inc.'s market capitalization?
Lantheus Holdings, Inc.'s market capitalization is approximately $6.7B.
Get the full picture on Lantheus Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.